Monthly Archives: June 2020

FINAL DEADLINE TOMORROW: The Schall Law Firm Announces it is Investigating Claims Against Akazoo S.A. and Encourages Investors with Losses of $100,000 to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / June 22, 2020 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class-action lawsuit against Akazoo S.A. ("Akazoo" or "the Company") (NASDAQ:SONG) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the Company's securities between September 11, 2019 and April 20, 2020, inclusive (the ''Class Period''), are encouraged to contact the firm before June 23, 2020.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at brian@schallfirm.com.

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. Akazoo overstated important financial measures, including revenue, profits, and cash holdings. The Company overstated the amount of music it held distribution rights for by a significant degree. It also has a much smaller userbase than it purports to have. The Company does not operate in 25 companies despite its continuing claims to do so and has closed its headquarters and various other offices. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Akazoo, investors suffered damages.

Join the case to recover your losses.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:
The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335
Cell: 424-303-1964
info@schallfirm.com

SOURCE: The Schall Law Firm

ReleaseID: 594775

IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces it is Investigating Claims Against Endo International plc and Encourages Investors with Losses of $100,000 to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / June 22, 2020 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Endo International plc ("Endo" or "the Company") (NASDAQ:ENDP) for violations of the securities laws.

The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Endo is the subject of a press release from the New York Department of Financial Services ("DFS") published on June 10, 2020. According to the DFS, it "has filed charges and initiated administrative proceedings against Endo International plc and its subsidiaries, Endo Health Solutions Inc., Endo Pharmaceuticals, Inc., and Par Pharmaceutical Companies, Inc." The charged on based on an ongoing DFS investigation of companies that created and perpetuated the opioid crisis." According to the release, "The DFS' statement of charges alleges that, like other opioid Manufactures, Endo . . . knowingly furthered a false narrative to legitimize opioids as appropriate for broad treatment of pain by downplaying their long-known addictive nature and risks"; "misrepresented the safety and efficacy of opioids, without legitimate scientific substantiation"; and "deployed a large sales force to target healthcare providers directly with these misrepresentations." Based on this news, shares of Endo fell sharply, harming investors.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at brian@schallfirm.com.

The class in this case has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:

The Schall Law Firm
Brian Schall, Esq.
310-301-3335
info@schallfirm.com
www.schallfirm.com

SOURCE: The Schall Law Firm

ReleaseID: 594772

SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against ProAssurance Corporation and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / June 22, 2020 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class-action lawsuit against ProAssurance Corporation ("ProAssurance" or "the Company") (NYSE:PRA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the Company's securities between April 26, 2019 and May 7, 2020, inclusive (the ''Class Period''), are encouraged to contact the firm before August 17, 2020.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at brian@schallfirm.com.

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. ProAssurance failed to maintain appropriate controls on underwriting and risk management, particularly in setting lose reserves. The Company was incapable of properly assessing a major healthcare account whose losses far exceeded assumptions that were made in underwriting. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about ProAssurance, investors suffered damages.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:
The Schall Law Firm
Brian Schall, Esq.
310-301-3335
info@schallfirm.com
www.schallfirm.com

SOURCE: The Schall Law Firm

ReleaseID: 594765

IMPORTANT SHAREHOLDER DEADLINE REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Ryder System, Inc. and Encourages Investors with Losses in Excess of $500,000 to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / June 22, 2020 The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class-action lawsuit against Ryder System, Inc. ("Ryder" or "the Company") (NYSE:R) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the Company's securities between July 23, 2015 and February 13, 2020, inclusive (the ''Class Period''), are encouraged to contact the firm before July 20, 2020.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at brian@schallfirm.com.

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. Ryder engaged in a pattern of overstating the residual value of its vehicles, which in turn inflated its financial results. The Company lacked any basis for the belief that its vehicles would sell for the values it assigned to them. The Company overstated these vehicles to such a degree that it was forced to take a $357 million depreciation charge related to the reduction of residual values in 2019. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Ryder, investors suffered damages.

Join the case to recover your losses.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:
The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335
info@schallfirm.com

SOURCE: The Schall Law Firm

ReleaseID: 594764

ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Wirecard AG and Encourages Investors with Losses of $100,000 to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / June 22, 2020 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Wirecard AG ("Wirecard" or "the Company") (OTC PINK:WCAGY)(OTC PINK:WRCDF) for violations of the securities laws.

The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Wirecard announced on June 18, 2020, that about 1.9 billion euros ($2.1 billion) in cash has gone missing, shocking investors. The Company admitted that loans of up to 2 billion euros could be terminated based on additional delay in publishing its financial results, which have already been delayed four times. Auditor Ernst & Young could not confirm the location of the missing cash, saying evidence of "spurious balance confirmations" had been provided. According to Wirecard, the missing money accounts to about a quarter of the Company's balance sheet. Shares of Wirecard have traded down by about 70% since the announcement.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at brian@schallfirm.com.

The class in this case has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:

The Schall Law Firm
Brian Schall, Esq.
310-301-3335
info@schallfirm.com
www.schallfirm.com

SOURCE: The Schall Law Firm

ReleaseID: 594762

The Gross Law Firm Announces Class Actions on Behalf of Shareholders of PRA, SRNE and CCL

NEW YORK, NY / ACCESSWIRE / June 22, 2020 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly-traded companies. Shareholders who purchased shares in the following companies during the dates listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment. Appointment as Lead Plaintiff is not required to partake in any recovery.

ProAssurance Corporation (NYSE:PRA)

Investors Affected: April 26, 2019 – May 7, 2020

A class action has commenced on behalf of certain shareholders in ProAssurance Corporation. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) ProAssurance lacked adequate underwriting process and risk management controls necessary to set appropriate loss reserves in its Specialty P&C segment; (ii) ProAssurance failed to properly assess a large national healthcare account that experienced losses far exceeding the assumptions made when the account was underwritten; and (iii) as a result, ProAssurance was subject to materially heightened risk of financial loss and reserve charges.

Shareholders may find more information at https://securitiesclasslaw.com/securities/proassurance-corporation-loss-submission-form/?id=7465&from=1

Sorrento Therapeutics, Inc. (NASDAQ:SRNE)

Investors Affected: May 15, 2020 – May 22, 2020

A class action has commenced on behalf of certain shareholders in Sorrento Therapeutics, Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) the Company's initial finding of "100% inhibition" in an in vitro virus infection will not necessarily translate to to success or safety in vivo, or in person; (ii) the Company's finding was not a "cure" for COVID-19; and (ii) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Shareholders may find more information at https://securitiesclasslaw.com/securities/sorrento-therapeutics-inc-loss-submission-form/?id=7465&from=1

Carnival Corporation & Plc (NYSE:CCL)

Investors Affected: September 26, 2019 – May 1, 2020

A class action has commenced on behalf of certain shareholders in Carnival Corporation & Plc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) the Company's medics were reporting increasing events of COVID-19 illness on the Company's ships; (2) Carnival was violating port of call regulations by concealing the amount and severity of COVID-19 infections onboard its ships; (3) in responding to the outbreak of COVID-19, Carnival failed to follow the Company's own health and safety protocols developed in the wake of other communicable disease outbreaks; (4) by continuing to operate, Carnival ships were responsible for continuing to spread COVID-19 at various ports throughout the world; and (5) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.

Shareholders may find more information at https://securitiesclasslaw.com/securities/carnival-corporation-loss-submission-form/?id=7465&from=1

The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a Company lead to artificial inflation of the Company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: dg@securitiesclasslaw.com
Phone: (212) 537-9430
Fax: (833) 862-7770

SOURCE: The Gross Law Firm

ReleaseID: 594758

Abivax Provides Business Update on Most Recent Achievements and Announces Positive Results of Annual Ordinary and Extraordinary General Meeting

Brazilian Health Regulatory Agency approves Phase 2b/3 study miR-AGE of ABX464 in COVID-19 patients
miR-AGE study has been approved by French and German regulators, and most recently by the British and Italian regulatory authorities
French government announced the selection of six COVID-19 projects to finance with a total of 78m EUR, with Abivax to receive 36m EUR
Final agreements for the 36m EUR funding have been signed with Bpifrance
Patient enrollment in ulcerative colitis Phase 2b trial post COVID-19 getting back on track, with 113 of 232 randomized to date
All resolutions presented during the general meeting were adopted

PARIS, FRANCE / ACCESSWIRE / June 22, 2020 / Abivax SA (Euronext Paris: FR0012333284 – ABVX), a late stage clinical biotechnology company harnessing the immune system to develop novel treatments for inflammatory diseases, viral diseases and cancer, today provides an update on its most recent clinical and financial achievements and developments and announces the positive results of the annual ordinary and extraordinary general meeting held on June 19, 2020.

The Brazilian Health Regulatory Agency (ANVISA – Agência Nacional de Vigilância Sanitária) approved the randomized, double-blind and placebo-controlled miR-AGE trial in high-risk COVID-19 patients. The study, already approved in France and Germany, will now be expanded to Brazil, where the number of new infections is still increasing rapidly. Approval for the miR-AGE trial has also been granted by the British Medicines and Healthcare Products Regulatory Agency (MHRA) and the Italian Medicines Agency (AIFA), with approval in Spain expected shortly.

Prof. Hartmut J. Ehrlich, M.D., CEO of Abivax, said: "By expanding the miR-AGE study to Brazil, currently the pandemic's most active country, we hope to be able to provide an efficient therapeutic option for the treatment of high-risk COVID-19 patients. We are also advancing the approval process in additional Latin American countries that are heavily affected by the rapid expansion of the pandemic. In parallel, patient recruitment is progressing according to our expectations for our ongoing clinical trials with ABX464, i.e. the Phase 2b in ulcerative colitis and Phase 2a in rheumatoid arthritis, as well as the US Phase 1/2 trial with ABX196 to treat hepatocellular carcinoma."

Prof. Jorge Kalil, M.D., Ph.D., Head of Immunology at the University Hospital in Sao Paulo and miR-AGE overall study coordinator in Brazil, added: "We are eager to start the miR-AGE trial in Brazil and to test this innovative and promising drug candidate for the benefit of all countries and patients affected by the COVID-19 pandemic, which is still globally present. We hope to see a positive effect from the early treatment with ABX464 in reducing the severity of the disease by inhibiting viral replication, preventing hyper-inflammation and thus the potential deadly acute respiratory distress syndrome and also by limiting potential long-term lung injury in patients."

Philippe Pouletty, M.D., Chairman of the Board of Abivax, said: "We are proud that Abivax's ABX464 was selected by the French government as a promising drug candidate for treatment of COVID-19. We wish to thank Bpifrance, the Secrétariat Général pour l'Investissement (SGPI) and the French government for their backing and support of Abivax. At the same time, while we are confident that ABX464 may have a positive impact by reducing the severity of COVID-19 sequelae, we remain prudent on expectations for the miR-AGE trial given the complexities surrounding treatment of COVID-19 disease. Progressing ABX464 development in chronic inflammatory diseases remains Abivax's corporate priority."

With regards to the financial situation of the Company, the final agreements with Bpifrance, the investment bank of the French state, have been signed following the French government's selection of six development projects for a potent COVID-19 treatment. These projects will be financed with a total of 78m EUR by the French state, of which Abivax will receive 36m EUR in non-dilutive funding for its 1,034-patient ABX464 Phase 2b/3 COVID-19 (miR-AGE) trial, manufacturing scale-up, as well as additional development costs related to other ABX464 studies and the potential filing of ABX464 Marketing Authorization Applications (MAA).

Abivax recently also announced a further 5m EUR non-dilutive financing from Société Générale in the form of a loan guaranteed by the French state (PGE – Prêts Garantis par l'Etat).

Didier Blondel, Chief Financial Officer of Abivax, said: "With the official signing of the final contracts with Bpifrance and the loan recently granted by Société Générale, Abivax's cash resources will fully finance the corporate objectives and current development plans until early 2021. We currently plan to continue to focus on sourcing additional non-dilutive financing options for the longer term."

The Company also announces today that it held its annual ordinary and extraordinary general meetings on June 19, 2020 behind closed doors, under the chairmanship of Dr. Philippe Pouletty, Chairman of the Board of Directors and without the physical presence of its shareholders due to COVID-19 social distancing practices.

All resolutions presented by the Board of Directors were adopted, including the compensation policy applicable to the Chief Executive Officer and the directors. Details of the voting results on all resolutions will be available on the company website.

About Abivax

Abivax, a clinical stage biotechnology company, is mobilizing the body's natural immune machinery to treat patients with autoimmune diseases, viral infections, and cancer. Abivax is listed on Euronext compartment B (ISIN: FR0012333284 – Mnémo: ABVX). Based in Paris and Montpellier, Abivax has two drug candidates in clinical development, ABX464 to treat severe inflammatory diseases, and ABX196 to treat hepatocellular carcinoma.
More information on the company is available at www.abivax.com. Follow us on Twitter @ABIVAX_.

Contacts

Abivax
Communications
Regina Jehle
regina.jehle@abivax.com
+33 6 24 50 69 63
Investors
LifeSci Advisors
Chris Maggos
chris@lifesciadvisors.com
+41 79 367 6254
Press Relations & Investors Europe
MC Services AG
Anne Hennecke
anne.hennecke@mc-services.eu
+49 211 529 252 22

Public Relations France
Actifin
Ghislaine Gasparetto
ggasparetto@actifin.fr
+33 6 21 10 49 24
Public Relations France
DGM Conseil
Thomas Roborel de Climens
thomasdeclimens@dgm-conseil.fr
+33 6 14 50 15 84
Public Relations USA
Rooney Partners LLC
Marion Janic
mjanic@rooneyco.com
+1 212 223 4017

DISCLAIMER

This press release contains forward-looking statements, forecasts and estimates (including patient recruitment) with respect to certain of the Company's programs. Although the Company believes that its forward-looking statements, forecasts and estimates are based on assumptions and assessments of known and unknown risks, uncertainties and other factors that have been deemed reasonable, such forward-looking statements, forecasts and estimates are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated in such forward-looking statements, forecasts and estimates. A description of these risks, contingencies and uncertainties can be found in the documents filed by the Company with the French Autorité des Marchés Financiers pursuant to its legal obligations including its registration document (Document de Référence). Furthermore, these forward-looking statements, forecasts and estimates are only as of the date of this press release. Readers are cautioned not to place undue reliance on these forward-looking statements. Abivax disclaims any obligation to update these forward-looking statements, forecasts or estimates to reflect any subsequent changes that the Company becomes aware of, except as required by law.
This press release is for information purposes only, and the information contained herein does not constitute either an offer to sell, or the solicitation of an offer to purchase or subscribe securities of the Company in any jurisdiction, in particular in France. Similarly, it does not give and should not be treated as giving investment advice. It has no connection with the investment objectives, financial situation or specific needs of any recipient. It should not be regarded by recipients as a substitute for exercise of their own judgement. All opinions expressed herein are subject to change without notice. The distribution of this document may be restricted by law in certain jurisdictions. Persons into whose possession this document comes are required to inform themselves about and to observe any such restrictions.

SOURCE: ABIVAX

ReleaseID: 594757

Elephant Hill and Luckbox Announces Completion of Second Tranche of Oversubscribed Subscription Receipts Offering

Not for distribution to U.S. newswire services or dissemination in the United States

CALGARY, AB / ACCESSWIRE / June 22, 2020 / Further to the press release dated June 10, 2020, Esports Limited ("Luckbox" or the "Company") and Elephant Hill Capital Inc. (TSXV:EH.P) ("Elephant Hill") are pleased to announce that Luckbox has completed the second tranche of its private placement offering of subscription receipts ("Subscription Receipts") led by Gravitas Securities Inc. and Beacon Securities Ltd. (the "Co-Lead Agents") as co-lead agent and co-bookrunners, on behalf of a syndicate of agents (collectively with the Co-Lead Agents, the "Agents") for additional gross proceeds of $502,220 (the "Brokered Financing"). Concurrently with the Brokered Financing, Luckbox completed a second tranche non-brokered offering of Subscription Receipts for additional gross proceeds of $125,430 (the "Non-Brokered Financing" and together with the Brokered Financing, the "Offering") resulting in the aggregate gross proceeds of the second tranche of the Offering being $627,650, bringing the total raised in the offering to date to $4,505,874. The Offering was completed in connection with the proposed business combination (the "Proposed Transaction") between Luckbox and Elephant Hill previously announced in a press release of Elephant Hill dated May 13, 2020, which transaction is intended to constitute Elephant Hill's "Qualifying Transaction" pursuant to Policy 2.4 of the TSX Venture Exchange (the "Exchange"). The Offering was heavily oversubscribed and subsequently upsized from the previously announced range of $2,000,000 to $3,000,000.

The Offering

Under the terms of the Brokered Financing between Luckbox and the Agent, Luckbox has to date issued 1,195,761 Subscription Receipts at a price of $0.42 per Subscription Receipt (the "Offering Price") for aggregate gross proceeds of $502,220. Concurrently, Luckbox has completed the Non-Brokered Financing of Subscription Receipts on the same terms as the Brokered Financing by issuing 298,607 Subscription Receipts at the Offering Price for aggregate gross proceeds of $125,430.

The proceeds of the Brokered Financing, together with funds raised in the Non-Brokered Financing, will be used for general corporate and working capital purposes.. The Offering is a condition precedent to the Proposed Transaction.

Each Subscription Receipt entitles the holder thereof to receive, upon satisfaction of the Escrow Release Conditions (as hereinafter defined) on or before the Escrow Release Deadline (as hereinafter defined), and without payment of additional consideration, one unit of Luckbox (each, a "Unit"). Each Unit will consist of one common share (each, an "Underlying Share") and one-half of one common share purchase warrant of Luckbox (each whole common share purchase warrant, an "Underlying Warrant"), with each Underlying Warrant being exercisable into one common share in the capital of Luckbox at a price of $0.63 for a period of 24 months from the date of the satisfaction of the Escrow Release Conditions (as hereinafter defined). Pursuant to the Proposed Transaction, each Underlying Share and Underlying Warrant will be exchanged on an equivalent basis, without further consideration, for common shares and warrants in the capital of Elephant Hill.

The gross proceeds of the Offering, less (i) 50% of the Agents' Fee (as defined below), which was paid to the Agents, and (ii) the expenses of the Agents incurred in connection with the Brokered Financing, which were paid to the Agents (collectively, the "Escrowed Proceeds") were delivered to and held by Computershare Trust Company (the "Escrow Agent"). The Escrowed Proceeds, together with all interest and other income earned thereon, are referred to herein as the "Escrowed Funds".

The remaining 50% of the Agents' Fee will be released from escrow to the Agents from the Escrowed Funds and the balance of the Escrowed Funds will be release from escrow to the Company upon satisfaction of customary escrow release conditions (the "Escrow Release Conditions") on or before 5:00 pm (Calgary time) on December 31, 2020 (the "Escrow Release Deadline").

In the event that (i) the Escrow Release Conditions are not satisfied on or before the Escrow Release Deadline, or (ii) if prior to such time, the Company advises the Agents or announces to the public that it does not intend to satisfy the Escrow Release Conditions, the Escrow Agent will return to holders of Subscription Receipts an amount equal to the aggregate Offering Price of the Subscription Receipts held by them and their pro rata portion of any interest earned thereon. The Company will be responsible and liable to the holders of Subscription Receipts for any shortfall between the aggregate Offering Price and the Escrowed Funds.

The Agents will receive a cash commission equal to 8.0% of the aggregate gross proceeds from the Brokered Financing (the "Agents' Fee"). Luckbox will also issue to the Agents that number of compensation options (the "Compensation Options") equal to 8.0% of the aggregate number of Subscription Receipts sold pursuant to the Brokered Financing. Each Compensation Option will entitle the holder thereof to acquire one Unit of the resulting issuer (the "Resulting issuer") at an exercise price of $0.42 for a period of 24 months following the date the Resulting Issuer common shares are listed on the Exchange.

Qualifying Transaction Update

Concurrently with the completion of the Offering, Elephant Hill continues to move expeditiously towards the closing of the Qualifying Transaction with Luckbox, as detailed in its press release dated May 12, 2020.

Mo Fazil, President and CEO for Elephant Hill commented, "As evidenced by the oversubscribed subscription receipts offering, we continue to be enthusiastic about our proposed business combination with Luckbox. The esports market continues to expand with each passing month and Luckbox is positioned to be one of the leading e-sports betting companies in an exciting growth industry."

About Luckbox

Luckbox is a private esports betting company, incorporated in the Isle of Man on April 25, 2019, and headquartered in the Isle of Man, with a fully licensed betting platform dedicated to serving the global esports community where fans and customers are able to bet, watch, and chat in a safe environment. Luckbox believes that it serves the single largest revenue category in esports today and derives its revenue from one of the most promising verticals in the esports industry. Luckbox has an experienced management team in both esports and betting and a dedicated esports user experience.

Esports Insider says: "Luckbox is one of the bookmakers at the forefront of esports at the moment, holding a full gambling licence and accepting bets from customers in over 100 territories. If the public listing goes ahead, all eyes will be on Luckbox when it comes to esports betting."

https://esportsinsider.com/2020/05/luckbox-tsx-venture-exchange/

Investors are cautioned that, except as disclosed in the disclosure document to be prepared in connection with the Proposed Transaction, any information released or received with respect to the Proposed Transaction may not be accurate or complete and should not be relied upon.

For further information, please contact:

Elephant Hill Capital Inc.
Mohammad Fazil, President, Chief Executive Officer, Director
Email: mofazil@gmail.com
Phone: (403) 613-7310

Esports Ltd.
Quentin Martin, Chief Executive Officer
Email: quentin@luckbox.com
Phone: (+44) 7498 181 863

NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

All information contained in this press release with respect to Elephant Hill and Luckbox was supplied by the parties, respectively, for inclusion herein, and Elephant Hill and its directors and officers have relied on Luckbox for any information concerning such party.

Completion of the Proposed Transaction is subject to a number of conditions, including but not limited to, TSXV acceptance and, if applicable, pursuant to the requirements of the TSXV, majority of the minority shareholder approval. Where applicable, the Proposed Transaction cannot close until the required shareholder and regulatory approval is obtained. There can be no assurance that the Proposed Transaction will be completed as proposed or at all.

Investors are cautioned that, except as disclosed in the management information circular or filing statement to be prepared in connection with the Proposed Transaction, any information released or received with respect to the Proposed Transaction may not be accurate or complete and should not be relied upon. Trading in the securities of the Corporation should be considered highly speculative.

This press release is not an offer of securities for sale in the United States. The securities described in this press release have not been registered under the U.S. Securities Act of 1933, as amended, and may not be offered or sold in the United States or to, or for the account or benefit of, U.S. persons (as defined in Regulation S under the U.S. Securities Act of 1933, as amended) absent registration or an exemption from registration. This press release shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of the securities in any jurisdiction where such offer, solicitation, or sale would be unlawful.

The TSX Venture Exchange Inc. has in no way passed upon the merits of the Proposed Transaction and has neither approved nor disapproved the contents of this press release.

Cautionary Note Regarding Forward-Looking Statements: This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. All statements in this news release, other than statements of historical facts, including statements regarding future estimates, plans, objectives, timing, assumptions or expectations of future performance, including the terms and conditions of the Proposed Transaction; the terms and conditions of the Proposed Financing; and future developments and the business and operations of the "Resulting Issuer" after the Proposed Transaction are forward-looking statements and contain forward-looking information. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as "intends" or "anticipates", or variations of such words and phrases or statements that certain actions, events or results "may", "could", "should", "would" or "occur". Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release, including that the terms and conditions of the Proposed Transaction will be as anticipated by management; the terms and conditions of the proposed Financing will be as anticipated by management; and future developments and the business and operations of the "Resulting Issuer" after the Proposed Transaction will be as anticipated by management. These forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information. Important factors that may cause actual results to vary, include, without limitation, that the terms and conditions of the Proposed Transaction will not be as anticipated by management or will not close at all; the terms and conditions of the Proposed Financing will not be as anticipated by management or will not close at all; and future developments and the business and operations of the "Resulting Issuer" after the Proposed Transaction will not be as anticipated by management. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial out-look that are incorporated by reference herein, except in accordance with applicable securities laws.

SOURCE: Elephant Hill Capital Inc.

ReleaseID: 594751

Top Car Insurance Discounts Offered By Insurers

LOS ANGELES, CA / ACCESSWIRE / June 22, 2020 / Compare-autoinsurance.org (https://compare-autoinsurance.org) has launched a new blog post that presents the top discounts offered by car insurance providers.

Car insurance is a frustrating but necessary factor in car ownership. Obtaining the best policy possible is not that easy and many drivers are likely to run into some common issues and questions about the process. Luckily, there are many discounts offered across the car insurance industry to make insurance policies more affordable.

For more info and free car insurance quotes, visit https://compare-autoinsurance.org/what-car-insurance-discounts-can-you-obtain-from-the-insurance-company

Car insurance is a frustrating but necessary factor in car ownership. Obtaining the best policy possible is not that easy and many drivers are likely to run into some common issues and questions about the process. Luckily, there are many discounts offered across the car insurance industry to make insurance policies more affordable.

Drivers who are shopping around for a new car insurance company and policy should check if the following discounts are offered and if they meet the eligibility requirements:

Loyalty discount. To get a loyalty discount, drivers should ask their insurers whether a discount is offered, how long they will need to be a customer to be eligible, and any other terms that might apply. Insurance companies apply the discount after a predetermined period of time, and some companies will increase the discount the longer the drivers remain a customer.
Good student discounts. High school and college students are often eligible for discounts. Insurers offer this discount to students with good grades because they believe that a good student is likely to be a more responsible driver than a mediocre or poor student.
Bundling or multipolicy discounts. Most insurance providers offer a discount for customers who purchase two or more policies together. Policyholders can bundle their car insurance policies with other policies such as homeowner's insurance, boat insurance, or renter's insurance.
Good driving discounts. Generally, there are two types of good driving discounts: those offered to drivers who maintain a clean driving record free of crashes and moving violations, and those offered to drivers who opt-in to tracking programs. Drivers who keep a clean driving record can save about 5% on their policies, while drivers who opt-in for a tracking program are likely to save way more.
Defensive driving discounts. Drivers who successfully complete an approved driver training course are eligible for a defensive driving discount. However, drivers should check if their insurers offer this discount to them.
Employer/ affinity group discounts. Drivers who work for a company that has negotiated a bulk rate with a certain insurance company are eligible for this type of discount. A typical affinity group discount can be anywhere from 5% to 20%, though the actual savings depend on the terms the employer negotiated with the insurer.
Teacher discounts. Many major auto insurance companies offer special discounts, rates, or perks, especially for teachers and educators.
Military and veteran discounts. Most car insurance providers offer special rates or discounts to active military personnel, veterans, and their families. Insurance providers can offer perks like discounts on vehicles parked on a military base and discounts on vehicles stored during active deployment.
Safety gear discounts. Unfortunately, safety equipment discounts aren't that common anymore. Most new vehicles are equipped with technology that reduces or minimizes the risk and impact of a crash. Only a few insurers offer specific discounts for vehicles with such features. Insurers say that, in general, customers with such vehicles already pay lower rates for vehicles with safety features such as anti-lock brakes.
Low mileage discounts. Insurance providers are offering this discount to drivers who drive less than a certain amount of miles, usually less than 15,000 miles per year.

For additional info, money-saving tips and free car insurance quotes, visit https://compare-autoinsurance.org/

Compare-autoinsurance.org is an online provider of life, home, health, and auto insurance quotes. This website is unique because it does not simply stick to one kind of insurance provider, but brings the clients the best deals from many different online insurance carriers. In this way, clients have access to offers from multiple carriers all in one place: this website. On this site, customers have access to quotes for insurance plans from various agencies, such as local or nationwide agencies, brand names insurance companies, etc.

"For many drivers, car insurance might be too expensive. Fortunately, insurance providers offer numerous discounts to make their policies more affordable", said Russell Rabichev, Marketing Director of Internet Marketing Company.

CONTACT:

Company Name: Internet Marketing Company
Person for contact Name: Gurgu C
Phone Number: (818) 359-3898
Email: cgurgu@internetmarketingcompany.biz
Website: https://compare-autoinsurance.org/

SOURCE: Internet Marketing Company

ReleaseID: 594709

NMS Consulting Announces Acquisition of UK Based Management Consultancy Firm, Moore Fleming Limited

Harry Moore Appointed, Senior Partner, Head of Europe and Global Corporate Turnaround and Transformation

BEVERLY HILLS, CA and LONDON, UK / ACCESSWIRE / June 22, 2020 / NMS Consulting, Inc. ("NMS") is pleased to announce the acquisition of Moore Fleming Limited ("Moore Fleming"), a United Kingdom based management consultancy specializing in operational turnaround, business transformation, capital advisory, succession planning and family business advisory services through its merger with NMS Consulting (Europe) Ltd. In addition, NMS is pleased to announce the formal appointment of Dr. Harry Moore as Senior Partner, Head of Europe and Global Corporate Turnaround and Transformation. Dr. Moore shall also directly oversee the European expansion of NMS Consulting which recently launched with the opening of an office in Berlin, with additional offices scheduled to open soon in Frankfurt and Paris.

Founded by Dr. Moore in 2001, Moore Fleming has a proven track record as a niche management consulting boutique firm advising a global client base. Dr. Moore is an experienced international strategist and corporate turnaround director with a substantial pedigree, having led business transformation teams at both KMPG and PwC. In addition, he has been sponsored by the UK government to manage initiatives that he designed to secure the future of enterprises in the SME sector in the UK which resulted in saving some 135 UK businesses. He has served as an advisor to Coutts Bank of London on matters concerning family businesses. He is also a senior industry advisor to the European Bank of Reconstruction and Development and was involved in the transformation of USSR businesses and the creation of modern Russia, advising companies throughout eastern Europe on western business practices.

Dr. Harry Moore, Senior Partner, Head of Europe and Global Corporate Turnaround and Transformation said "This is a great move for Moore Fleming. It's integration into NMS Consulting Inc will enable further international expansion. NMS is a serious niche player in business transformation bringing fresh and innovative solutions for accelerated performance improvement into the SME and middle market sectors across Europe. I am personally very excited about heading up the new Pan- European consultancy service as well as a new global business transformation team."

"We continue to invest in new talent and innovative solutions to best serve our global client base and I couldn't think of a better partner to lead our European expansion than Harry Moore and the addition of Moore Fleming" said, Trevor M. Saliba, Managing Partner "Harry is a leader with a proven track record and pedigree as a practitioner. The addition of Moore Fleming to bolster our European operations led by Harry is reflective of our steadfast commitment to providing clients with the local expertise, global reach and support from some of the most talented subject matter experts across multiple industries."

About NMS Consulting

NMS Consulting is a global strategic advisory and management consulting firm focused on delivering client solutions across three business units: management consulting, corporate advisory and strategic communications. The firm provides strategic counsel to private and public companies, governments, philanthropic organizations and the individuals who lead them.

For more information, please visit www.nmsconsulting.com.

Media Contact:

USA
Lili Swanson
+1.310.855.0020
info@nmsconsulting.com

EUROPE
Sophia Binder
+44 20 3895 3540
sbinder@nmsconsulting.com

SOURCE: NMS Consulting, Inc.

ReleaseID: 594746